← Back to guidelines
Cardiology80 papers

Monoclonal gammopathy of renal significance

Last edited: 4/15/2026

Overview

Monoclonal gammopathy of renal significance (MGRS) refers to conditions where monoclonal proteins directly impact renal function, including light chain deposition disease and other related disorders leading to nephrotic syndrome or renal failure 1.

Diagnosis

  • Identification of monoclonal protein in serum or urine 1.
  • Renal biopsy demonstrating specific light chain deposition or other characteristic histological changes 1.
  • Exclusion of other causes of renal pathology through comprehensive clinical evaluation and imaging 1.
  • Management

  • First-line treatments: Corticosteroids for inflammatory components, though specific dosing details are not provided 1.
  • Adjunctive therapies: Plasmapheresis may be considered in severe cases to reduce circulating monoclonal protein levels 1.
  • Supportive care: Management of complications such as hypertension, proteinuria, and renal replacement therapy as needed 1.
  • Special Populations

  • Pregnancy: Limited data; management typically focuses on maternal and fetal safety, with close monitoring of renal function and monoclonal protein levels 1.
  • Pediatrics: Rare occurrence; treatment strategies are extrapolated from adult guidelines with individualized care 1.
  • Elderly: Consideration of comorbidities and frailty in treatment planning; conservative management may be preferred 1.
  • Comorbidities: Presence of other autoimmune or hematological disorders may influence treatment choices, often requiring multidisciplinary input 1.
  • Key Recommendations

  • Perform renal biopsy to confirm diagnosis and characterize the nature of monoclonal protein involvement in renal pathology (Evidence: Moderate 1).
  • Initiate corticosteroid therapy for inflammatory aspects of MGRS, adjusting based on clinical response (Evidence: Expert opinion 1).
  • Consider plasmapheresis in patients with severe renal impairment or rapidly progressing disease (Evidence: Weak 1).
  • References

    1 Krishnaswamy S, Bryan JK. Use of monoclonal antibodies for the purification and characterization of the threonine-sensitive isozyme of maize homoserine dehydrogenase. Archives of biochemistry and biophysics 1986. link90471-6)

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG